News & Events

• October 25, 2018
  

  FNIH Biomarkers Consortium and Critical Path Institute Achieve the First Ever Qualification of a Clinical Safety Biomarker by the U.S. Food and Drug Administration

  Major Milestone will Improve Detection of Drug-Induced Acute Kidney Injury in Clinical Trials.     October 25, 2018 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC) have received the first ever qualification of a clinical safety biomarker awarded by......
• September 25, 2018
  

  UA Colleges of Law and Pharmacy, Critical Path Institute, Launch Graduate Certificate Program in Regulatory Science

  Designed for graduate students and working professionals, the certificate program provides specialized training in navigating the path from research to bringing medical products to market.     TUCSON, Ariz., September 25, 2018 — The University of Arizona and the Critical Path Institute have launched a new online graduate certificate program designed to equip students and......
• September 17, 2018
  

  Critical Path Institute and SIGNATOPE GmbH Team Up to Advance Research on Biomarkers for Drug-induced Organ Injuries

      TUCSON, Ariz. and REUTLINGEN, September 17, 2018 — Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) and SIGNATOPE GmbH are excited to announce a new project, joining efforts on analyzing and qualifying promising protein safety biomarkers in mouse, rat, dog, monkey, and human. The work is expected to increase understanding of drug-induced toxicities......
• September 6, 2018
  

  Doris Duke Charitable Foundation Awards Grant to Critical Path Institute to Advance Therapies for Sickle Cell Disease

  Contacts: Kissy Black, Critical Path Institute kissyblack@lotosnile.com, 615.298.1144 Kristin Roth-Schrefer, Communications Director kschrefer@ddcf.org, 212.974.7003 Nina Chung, Communications Associate nchung@ddcf.org, 212.974.7006   Critical Path Institute (C-Path) Will Plan a Consortium of Stakeholders Focused on Developing Therapies for Sickle Cell Disease   NEW YORK, September 6, 2018 — In a continuing effort to spur advancements in treating......
• July 26, 2018
  

  First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trials

  FOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 kissyblack@lotosnile.com   Tucson, AZ — July 26, 2018 – The Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), in partnership with Parkinson’s UK, announces that the European Medicines Agency (EMA) has issued a positive qualification opinion on an imaging test (biomarker) as a tool to enrich......